David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
RAHWAY, N.J., July 01, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Orion Corporation ("Orion") today announced that notice has been provided of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, and other candidates targeting CYP11A1 into an exclusive global license for Merck.
RAHWAY, N.J., July 01, 2024--Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30